vitalcare®
INFUSION SERVICES
of CROWN POINT

Alpha-1 Therapy
in the home

As a leader in the infusion industry, Vital Care of Crown Point provides services and care to patients diagnosed with Alpha-1 antitrypsin deficiency, a rare genetic disorder. Our team will work with the provider to customize a care plan designed to optimize patient outcomes, reduce costs, and increase patient and provider satisfaction.

A patient should be tested for Alpha-1 if they have:

- Emphysema, Chronic Obstructive Pulmonary Disease (COPD) Or Chronic Bronchitis
- Bronchiectasis
- Unexplained Liver Disease
- A family history Of Liver Disease
- A blood relative diagnosed With Alpha-1
- Panniculitis (skin disease)

For our home Alpha-1 therapy patients, Vital Care Crown Point provides

- Quick benefits investigation
- Prior authorization initiation
- Letters of medical necessity
- Appeal letters/support
- Patient/caregiver training
- 24 hours, 7 days a week call service
- In home therapy administration and nursing coordination

vitalcare®
INFUSION SERVICES
of CROWN POINT

Vital Check

Alpha-1 Antitrypsin Deficiency

Essential Data

To process the referral, please provide the following information:

- Patient demographic information
- Copy of insurance card
- History and physical – to include clinical manifestations, height, weight, family history of Alpha-1 or COPD, treatment history, infection history, hospitalization history
- Diagnosis of emphysema – COPD does not qualify unless there is a family history
- Diagnosis of Alpha-1 Antityrpsin Deficiency ICD-10 E88.01
- Never or ex-smoker
  *If ex-smoker, demonstration of completing a smoking cessation program lasting one year or longer
- Pulmonary Function Test – FEV1 specifically
- Serum AAT level
- Genotype, phenotype
- Chest x-ray
- Prescription – drug name, dose, frequency
- Previous treatments and clinical outcomes of each

AAT serum level < 11um Consideration for treatment is independent of phenotype/genotype and based on level and presence of obstructive disease
**Patients with normal or nearly normal PFTs can be treated if they experience rapid decline in lung function (change in FEV1 > 120mL/year)

Alpha-1 replacement is contraindicated in patients with IgA deficiency. IgA levels should be checked prior to starting patients on therapy.

Crown Point
219.295.4080
219.600.1800